Provinical Medical Genetics Program, BC Women's Hospital and Health Centre, University of British Columbia, 4500 Oak Street, Vancouver, BC, V6H 3N1, Canada.
Curr Osteoporos Rep. 2017 Oct;15(5):419-424. doi: 10.1007/s11914-017-0392-x.
This review highlights how skeletal dysplasias are diagnosed and how our understanding of some of these conditions has now translated to treatment options.
The use of multigene panels, using next-generation sequence technology, has improved our ability to quickly identify the genetic etiology, which can impact management. There are successes with the use of growth hormone in individuals with SHOX deficiencies, asfotase alfa in hypophosphatasia, and some promising data for c-type natriuretic peptide for those with achondroplasia. One needs to consider that a patient with short stature has a skeletal dysplasia as options for management may be available.
本文重点介绍了骨骼发育不良的诊断方法,以及我们对某些骨骼发育不良的认识如何转化为治疗选择。
使用多基因面板,结合下一代测序技术,提高了我们快速识别遗传病因的能力,这可能会影响治疗方案。在 SHOX 缺陷的个体中使用生长激素、在低磷酸酯酶症中使用 asfotase alfa 以及在软骨发育不全患者中使用 C 型利钠肽都取得了成功。人们需要考虑到身材矮小的患者可能患有骨骼发育不良,因为可能有可供选择的治疗方案。